Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 Following the successful launch of ... webinar to introduce its new product and demonstrate its ... , Launched in September, Formedix On Demand Services is ... trial automation tools. For the first time, these market-leading ... by introducing Formations – a revolutionary new token-based payment ...
(Date:10/31/2014)... Brady (NYSE:BRC), a global ... a new video testimonial on the effectiveness ... a research technician at the BloodCenter of Wisconsin discusses ... and storing hundreds of thousands of samples, and how ... , “At Brady, we design our label materials with ...
(Date:10/31/2014)... ORLANDO, Fla. , Oct. 31, 2014 /PRNewswire/ ... firm owned by Tavistock Group, celebrated the groundbreaking of ... Nona Medical City. The 92,000-square-foot, ... Central Florida designed specifically ... Located in the heart of the 650-acre Lake ...
(Date:10/30/2014)... October 30, 2014 Investor-Edge has ... (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN ... Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,549.23, down 0.33%, the Dow Jones Industrial Average declined ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Brady Debuts New Lab Label Testimonial Video 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... July 15, 2011 Biocept, Inc. announced today that ... President, Finance and Chief Financial Officer.  As CFO, Mr. ... accounting, finance, treasury, investor relations, risk management and information ... leadership experience in helping to build life science companies. ...
... July 15, 2011 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, today announced that the ... to succeed John Pappajohn as Chairman of the Board. ... immediately. Dr. Sayare has been a member ...
... July 14, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, ... Phase 1/2 trial for BMN 673 for the treatment of ... is ongoing. "We are excited to be ...
Cached Biology Technology:Biocept, Inc. Announces New CFO 2Biocept, Inc. Announces New CFO 3Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors 2Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors 3BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies 2BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies 3
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... reveals new research potential of the Barcode of ... in the Biodiversity Data Journal ... format and imported these into a human-readable text developed ... (PWT). Data were used to study the species distributions ... Microgastrinae subfamily. , BOLD is originally designed to support ...
(Date:10/29/2014)... world compete with members of their own species. ... invest into their competitive ability. Some individuals are ... high-quality resources, while others seem to avoid competition, ... that are left over for them. Moreover, the ... seems to fluctuate considerably over time. A theoretical ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... the German Southwest, is the most innovative region in ... of 4.4 % of the State,s GDP is invested ... countries all around the world. Baden-Wrttemberg offers the highest ... present examples of the State,s excellence in research and ...
... University of the Negev researcher Dr. Taleb Mokari, a ... and Technology, has been awarded a prestigious Krill Prize ... the Prize for his work on developing novel nanostructures ... a senior lecturer in BGU,s Department of Chemistry. His ...
... journal ( PNAS ) published an article describing how the ... between microbes and the body,s own structures. The basis of ... components were discovered over 30 years ago and has ... groups at the University of Helsinki, Finland. ...
Cached Biology News:Science news from the German Southwest: Baden-Wuerttemberg at the 2011 AAAS Annual Meeting 2Host or foreign -- the body's frontline defense mechanism understood 2
... The Fujifilm Life Science FLA-5100 imaging system ... as large as 40 x 46cm at ... microns. This system is especially suitable for ... general array analysis for genomics., Fuji s ...
... Thermocycler provides high speed and excellent temperature ... a TGradient Thermocycler can be run without ... a silver block for 48 or 96 ... plates or in-situ applications are available. The ...
... inL10 Workstation from Caliper represents a revolutionary ... the first time the ability to generate ... to changing conditions. In addition, each ... due to changes in temperature, and offers ...
... devices for the fast and reliable clarification/filtration of ... 500 l. They can be used in fixed ... Features: High-flux Polyethersulphonemembrane 0.8 ... volume ( Fast and reproducible performance ...
Biology Products: